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B-cell lymphoma in children accounts for about 10% of all pediatric malignancies.
Chemotherapy has been very successful leading to an over-all 5-year survival between 80
and 90% depending on lymphoma type and extent of disease.Therapeutic toxicity remains
high calling for better targeted and thus less toxic therapies. Therapeutic antibodies have
become a standard element of B-cell lymphoma therapy in adults. Clinical experience in
pediatric lymphoma patients is still very limited. This review outlines the rationale for anti-
body treatment of B-cell lymphomas in children and describes potential target structures
on B-cell lymphoma cells. It summarizes the clinical experience of antibody therapy of B-
cell lymphoma in children and gives an outlook on new developments and challenges for
antibody therapy of pediatric B-cell lymphoma.
Keywords: pediatric B-cell lymphoma, therapeutic antibodies, cancer therapeutics, individualized medicine, cancer
immunotherapy
RATIONALE FOR ANTIBODY THERAPY OF B-CELL
LYMPHOMAS IN CHILDREN
Pediatric lymphomas account for 10% of all pediatric malignan-
cies (Howlader et al., 2009). Approximately 60% are of B-cell
origin. They comprise Hodgkin and B-Non-Hodgkin lymphomas
(HL and B-NHL). Among B-NHL Burkitt lymphomas are the
most frequent, followed by diffuse large B-cell lymphomas. Cur-
rent B-cell lymphoma treatment in children consists of four
modalities: chemotherapy, surgery, radiotherapy, and in some
cases allogeneic stem cell transplantation (Reiter, 2007; Carbone
et al., 2011; Miles et al., 2012; Shankar and Daw, 2012). With
current treatment protocols, overall 5-year event-free survival of
pediatric Hodgkin and B-Non-Hodgkin lymphoma patients is
between 80 and 90% (Reiter, 2007; Carbone et al., 2011; Miles
et al., 2012; Shankar and Daw, 2012). In view of this high cure
rate, current treatment protocols focus on reducing chemother-
apy intensity without decreasing overall and event-free survival.
However, a relevant further reduction of chemotherapy inten-
sity with current chemotherapeutics is not very likely. In children
late effects of chemotherapy are particularly important, calling
for development of new therapeutic options with reduced tox-
icity. Since chemotherapeutic drugs target not only tumor but
also healthy cells, they have a number of side effects. Mainly
rapidly dividing cells of the body are affected resulting in sig-
nificant toxicity such as cytopenia (leading to increased bleed-
ing tendency and increased risk of infections), gastrointestinal
mucositis, cardiac, kidney or liver toxicity, reduced fertility, and
alopecia. Treatment may even be postponed because of criti-
cally low immune cells or infectious complications. An impor-
tant long term side effect is the increased risk of secondary
malignancies. Allogeneic stem cell transplantation can be accom-
panied by severe acute and chronic toxicity (infections, non-
engraftment, acute, and chronic graft versus host disease) resulting
in treatment-related mortality of approximately 10–20%, depend-
ing on comorbidities and best available donor-match (Satwani
et al., 2012). Limited therapeutic options for relapsed disease are
another major treatment challenge often leading to poor prog-
nosis. Hence, there is a medical need for new, better targeted
therapies. One form of targeted therapy that over the past decade
has been increasingly recognized as being effective in cancer treat-
ment is monoclonal antibody therapy (Weiner et al., 2010; Scott
et al., 2012). Monoclonal antibodies contain uniform variable
regions and are thus specific for a single epitope (Kohler and
Milstein, 1975, 2005). Directed against a tumor-specific anti-
gen, these antibodies can target and destroy tumor cells, ideally
without harming healthy tissue. To reduce antibody inactivation
by the human immune system originally murine monoclonal
antibodies can be genetically modified to resemble the human
counterpart (humanized or chimeric antibodies). Monoclonal
antibodies can be produced in pharmaceutical grade using recom-
binant DNA technology (Chon and Zarbis-Papastoitsis, 2011).
The optimal B-cell lymphoma target antigen should be expressed
on the cell surface, so it can easily be reached by the antibody. It
should be uniquely or preferentially (over-) expressed by malig-
nant B-cells. There should be little or no expression by B-cell
precursors enabling reversible B-cell depletion and fast repopu-
lation after therapy. Even after antibody binding expression of
the target antigen should remain high (it should not shed or
internalize in response to antibody binding). Finally, the anti-
gen should be essential for B-cell lymphoma cell survival or
homeostasis to reduce the likelihood of antigen loss resulting
in lymphoma immune escape variants. In case of nodular scle-
rosis classical Hodgkin lymphoma antibodies targeting cells of
the tumor microenvironment can also be a therapeutic option.
This increases the number of potential targets and applicable
anti-lymphoma antibodies.
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The exact working mechanism for antibody-mediated lym-
phoma cell destruction may vary between different therapeu-
tic antibodies. In general, antibody-dependent cell-mediated
and complement-dependent cytotoxicity, phagocytosis by Fc-
receptor-expressing immune cells, antigen cross-presentation, and
apoptosis induction are all thought to contribute to the effective-
ness of antibody treatment (Weiner et al., 2010). Side effects of
reversible B-cell depletion are considered to be tolerable, especially
since immunoglobulins can be substituted to prevent infections.
AVAILABLE THERAPEUTIC ANTIBODIES TARGETING
PEDIATRIC B-CELL LYMPHOMAS
Truly B-cell lymphoma specific targets have not yet been identi-
fied. All available therapeutic antibodies target proteins that are
also expressed by normal B-cells. Expression may be universal
(e.g., CD19) or restricted to B-cell subpopulations (e.g., CD30).
Possible side effects of lymphoma antibody therapy are therefore
a direct consequence of target protein expression by normal B-
cells. B-cell lymphoma surface molecules that at least partly fulfill
the above mentioned requirements for antibody targets are CD19,
CD20, CD21, CD22, and CD30 (see Table 1 for an overview).
CD19
CD19 forms the B-cell co-receptor together with CD21 and CD81.
Anti-CD19 antibodies have in vitro and in vivo (mouse models)
activity against CD19-expressing lymphomas (Horton et al., 2008;
Ward et al., 2011). A CD19 antibody-drug conjugate (SAR3419)
has recently been tested in a phase I trial in adult lymphoma
patients (Younes et al., 2012a). Six of 35 patients achieved partial
or complete remissions. CD19 is expressed by most B-cell lym-
phomas and all normal B-cells. A bispecific anti-CD19/anti-CD3
antibody (Blinatumomab) has shown good clinical results in adult
lymphoma patients alone (Bargou et al., 2008) and in combination
with the anti-CD20 antibody Rituximab (d’Argouges et al., 2009).
When given alone to relapsed adult NHL patients Blinatumomab
induced four complete and seven partial tumor regressions among
38 patients treated. These effects were dose-dependent (Bargou
et al., 2008). Handgretinger et al. (2011) report induction of com-
plete remission in three children with post-stem cell transplan-
tation acute lymphocytic leukemia relapse after treatment with
Blinatumomab. CD19 can form heterodimers with CD21. High
CD21 expression on lymphomas has been shown to inhibit inter-
nalization of anti-CD19 antibodies into lymphoma cells leading to
reduced efficacy of anti-CD19-drug conjugates (Ingle et al., 2008).
However, recently Gerber et al. (2009) reported activity of an anti-
CD19-auristatin-conjugate antibody (hBU12-vcMMAE) against
lymphoma cells even in the presence of high CD21 expression.
CD20
CD20 is expressed by almost all pediatric B-NHL (Lones et al.,
2000; Swerdlow et al., 2008) and by normal B-cells. Its precise cel-
lular role remains to be elucidated. CD20 induces transmembrane
Calcium flux, either directly by functioning as a Calcium channel
or indirectly by modifying the function of other Calcium channels
(Bubien et al., 1993; Li et al., 2003; Walshe et al., 2008).
Most clinical experience exists for the anti-CD20 antibody
Rituximab. It was FDA-approved for the treatment of relapsed
or refractory low-grade or follicular B-NHL in adults in 1997.
Anti-CD20 treatment leads to profound B-cell depletion. Ritux-
imab is used successfully for treatment of adult B-cell lymphomas
and B-cell-mediated autoimmune diseases. Pharmacokinetics and
-dynamics of Rituximab have been studied in adult patients
(McDonald et al., 2010; Tran et al., 2010; Jäger et al., 2012).
Pediatric pharmacokinetic and -dynamic data are very limited
(Pranzatelli et al., 2010). Consequently, the adult dose is usually
given also to children, adjusted for body surface. A radiolabeled
anti-CD20 antibody (90yttrium-ibrituxomab-tiuxetan) has been
tested in a phase I study in children with relapsed and refractory
CD20-positive NHL (Cooney-Qualter et al., 2007). Patients did
not experience dose-limiting toxicity. The authors have designed
a phase II study to further evaluate safety and clinical efficacy of
radiolabeled anti-CD20 antibody.
CD21
CD21 is complement receptor-2 and forms part of the B-cell
co-receptor complex. It is expressed by mature B-cells, some
B-cell lymphomas, and thymocytes, a subset of peripheral T-
lymphocytes (Fischer et al., 1999). The anti-CD21 antibody-131I-
conjugate 131I-OKB7 was evaluated in a phase I study in 18 adult
lymphoma patients. Antitumor responses to a varying degree were
observed in 13 of 18 patients (Czuczman et al., 1993). However,
phase II study results have not been published.
CD22
CD22 is a sialic acid-binding immunoglobulin-like lectin
(SIGLEC) and functions as an immune inhibitory receptor on
B-cells (Poe and Tedder, 2012). It is expressed by all mature B-cell
populations and some B-cell lymphomas. CD22 is endocytosed
upon ligand binding. Therapeutic monoclonal anti-CD22 anti-
bodies conjugated to a cytotoxic agent (Inotuzumab ozogamicin,
CMC-544) have shown anti-lymphoma efficacy in a phase I study
in adult B-NHL patients (Advani et al., 2010). Treatment data for
pediatric lymphoma patients have not been published. Recently, de
Vries et al. (2012) described efficient killing of primary pediatric
B-cell precursor ALL cells by CMC-544. Epratuzumab, another
anti-CD22 antibody, has shown clinical efficacy in the reinduc-
tion therapy in children with All in bone marrow relapse (Raetz
et al., 2008) and in combination with Rituximab and chemother-
apy in the treatment of adults with diffuse large B-cell lymphoma
(Micallef et al., 2011).
CD30
The T- and B-lymphocyte activation antigen CD30 is expressed by
mononuclear Hodgkin cells and multinucleated Reed-Sternberg
cells (Swerdlow et al., 2008). CD30 is a member of the tumor
necrosis factor receptor superfamily. An anti-CD30 antibody
(SGN-30) showed antitumor activity in vitro and in Hodgkin
lymphoma animal models (Wahl et al., 2002). The clinical effects
in lymphoma patients, however, were disappointing (Wahl et al.,
2002; Bartlett et al., 2008; Forero-Torres et al., 2009). Only when
it was conjugated to a cytotoxic drug (monomethyl auristatin E)
anti-Hodgkin lymphoma activity was observed in patients (Younes
et al., 2010). The anti-CD30 antibody-drug conjugate Brentux-
imab vedotin was FDA-approved in 2011 for the treatment of adult
Frontiers in Oncology | Pediatric Oncology April 2013 | Volume 3 | Article 68 | 2
Meyer-Wentrup et al. Antibody therapy of pediatric B-cell lymphoma
Ta
b
le
1
|P
u
ta
ti
ve
an
ti
b
o
d
ie
s
fo
r
B
-c
el
ll
ym
p
h
o
m
a
th
er
ap
y
in
ch
ild
re
n
.
Ta
rg
et
ed
an
ti
ge
n
T
h
er
ap
eu
ti
c
an
ti
b
o
d
y
P
u
b
lis
h
ed
re
su
lt
s
fo
r
p
ed
ia
tr
ic
ly
m
p
h
o
m
a
p
at
ie
n
ts
(r
ef
er
en
ce
s/
FD
A
p
h
as
e
st
u
d
y
p
er
fo
rm
ed
)
Tr
ia
ls
o
p
en
fo
r
p
ed
ia
tr
ic
ly
m
p
h
o
m
a
p
at
ie
n
ts
(F
D
A
p
h
as
e,
cl
in
ic
al
tr
ia
ls
.
go
v
Id
en
ti
fi
er
)
C
lin
ic
al
ex
p
er
ie
n
ce
in
o
th
er
p
ed
ia
tr
ic
d
is
ea
se
s
FD
A
-
ap
p
ro
ve
d
fo
r
ad
u
lt
s
M
O
N
O
S
P
E
C
IF
IC
C
D
19
SA
R
34
19
(d
ru
g-
co
nj
ug
at
e)
N
o
N
o
Ye
s,
ph
as
e
2
st
ud
y
op
en
fo
r
le
uk
em
ia
pa
tie
nt
s
≥1
6
ye
ar
s
(N
C
T0
14
40
17
9)
N
o
S
G
N
-C
D
19
A
(d
ru
g-
co
nj
ug
at
e)
N
o
Ye
s,
ph
as
e
1
(N
C
T0
17
86
13
5)
N
o
N
o
C
D
20
R
itu
xi
m
ab
Ye
s
(M
ei
nh
ar
dt
et
al
.,
20
10
;G
ol
dm
an
et
al
.,
20
12
),
ph
as
e
1/
2
st
ud
ie
s
Ye
s
Ye
s
Ye
s
(ly
m
ph
om
a)
Im
m
un
e
th
ro
m
bo
cy
to
pe
ni
c
pu
rp
ur
a
(B
en
ne
tt
et
al
.,
20
06
;P
at
el
et
al
.,
20
12
)
P
ha
se
3
(N
C
T0
15
16
58
0)
A
ut
oi
m
m
un
e
di
se
as
es
(J
an
ss
on
et
al
.,
20
11
)
P
ha
se
2/
3
N
C
T0
15
95
04
8
S
ev
er
e
re
fr
ac
to
ry
ju
ve
ni
le
id
io
pa
th
ic
ar
th
rit
is
(A
le
xe
ev
a
et
al
.,
20
11
)
P
ha
se
2
N
C
T0
17
00
94
6
S
te
ro
id
-a
nd
ca
lc
in
eu
rin
-d
ep
en
de
nt
ne
ph
rit
ic
sy
nd
ro
m
e
(R
av
an
ie
t
al
.,
20
11
)
P
ha
se
2
N
C
T0
00
01
33
7
Im
m
un
os
up
pr
es
si
on
re
la
te
d
ly
m
ph
op
ro
lif
er
at
iv
e
di
se
as
e
(M
es
sa
he
le
t
al
.,
20
06
)
Sy
st
em
ic
lu
pu
s
er
yt
he
m
at
os
us
(W
ill
em
s
et
al
.,
20
06
)
P
ha
se
2
N
C
T0
06
54
73
2
Ju
ve
ni
le
de
rm
at
om
yo
si
tis
(O
dd
is
et
al
.,
20
13
)
P
ha
se
2
N
C
T0
10
09
97
0
Po
st
-t
ra
ns
pl
an
t
ly
m
ph
op
ro
lif
er
at
iv
e
di
so
rd
er
(G
up
ta
et
al
.,
20
10
)
To
si
tu
m
om
ab
an
d
13
1
I-t
os
itu
m
om
ab
(d
ru
g-
co
nj
ug
at
e)
N
o
N
o
N
o
Ye
s
(ly
m
ph
om
a)
90
Y-
Ib
rit
um
om
ab
tiu
xe
ta
n
(d
ru
g-
co
nj
ug
at
e)
Ye
s
(C
oo
ne
y-
Q
ua
lte
r
et
al
.,
20
07
)
N
o
N
o
Ye
s
(ly
m
ph
om
a)
O
bi
nu
tu
zu
m
ab
N
o
N
o
N
o
N
o
C
D
21
13
1I
-O
K
B
7
N
o
N
o
N
o
N
o
(C
on
tin
ue
d)
www.frontiersin.org April 2013 | Volume 3 | Article 68 | 3
Meyer-Wentrup et al. Antibody therapy of pediatric B-cell lymphoma
Ta
b
le
1
|C
o
n
ti
n
u
ed
Ta
rg
et
ed
an
ti
ge
n
T
h
er
ap
eu
ti
c
an
ti
b
o
d
y
P
u
b
lis
h
ed
re
su
lt
s
fo
r
p
ed
ia
tr
ic
ly
m
p
h
o
m
a
p
at
ie
n
ts
(r
ef
er
en
ce
s/
FD
A
p
h
as
e
st
u
d
y
p
er
fo
rm
ed
)
Tr
ia
ls
o
p
en
fo
r
p
ed
ia
tr
ic
ly
m
p
h
o
m
a
p
at
ie
n
ts
(F
D
A
p
h
as
e,
cl
in
ic
al
tr
ia
ls
.
go
v
Id
en
ti
fi
er
)
C
lin
ic
al
ex
p
er
ie
n
ce
in
o
th
er
p
ed
ia
tr
ic
d
is
ea
se
s
FD
A
-
ap
p
ro
ve
d
fo
r
ad
u
lt
s
C
D
22
In
ot
uz
um
ab
O
zo
ga
m
ic
in
(d
ru
g-
co
nj
ug
at
e)
N
o
N
o
N
o
N
o
E
pr
at
uz
um
ab
N
o
N
o
N
o
N
o
M
ox
et
um
om
ab
pa
su
do
to
x
(d
ru
g-
co
nj
ug
at
e)
N
o
Ye
s,
ph
as
e
1
(N
C
T0
06
59
42
5)
N
o
N
o
C
D
30
B
re
nt
ux
im
ab
ve
do
tin
(d
ru
g-
co
nj
ug
at
e)
N
o,
ph
as
e
1
st
ud
y
pe
rf
or
m
ed
Ye
s,
ph
as
e
1/
2
(N
C
T0
14
21
66
7)
(N
C
T0
14
92
08
8)
N
o
Ye
s
(ly
m
ph
om
a)
C
TL
A
-4
Ip
ili
m
um
ab
N
o
Ye
s,
ph
as
e
1
(N
C
T0
14
45
37
9)
N
o
Ye
s
(m
el
an
om
a)
P
D
-1
B
M
S
-9
36
55
8
N
o
N
o
N
o
N
o
B
IS
P
E
C
IF
IC
C
D
19
/C
D
3
B
lin
at
um
om
ab
N
o
N
o
Ye
s,
ph
as
e
1
an
d
2
st
ud
y
op
en
fo
r
le
uk
em
ia
pa
tie
nt
s
(N
C
T0
14
71
78
2)
N
o
Frontiers in Oncology | Pediatric Oncology April 2013 | Volume 3 | Article 68 | 4
Meyer-Wentrup et al. Antibody therapy of pediatric B-cell lymphoma
patients with Hodgkin lymphoma after failure of autologous stem
cell transplantation or after failure of at least two prior multi-
agent chemotherapy regimens in patients who are not candidates
for hematopoietic stem cell transplantation (Younes et al., 2010,
2012b). Currently, two phase 1 studies are recruiting pediatric
Hodgkin lymphoma patients (Table 1).
CURRENT CLINICAL EXPERIENCE WITH ANTIBODY THERAPY
OF B-CELL LYMPHOMAS IN CHILDREN
The largest body of clinical data exists for Rituximab (anti-CD20).
In adults, Rituximab has been applied successfully to treat B-cell
lymphomas (Coiffier et al., 2002; Pfreundschuh et al., 2006, 2008)
and has become part of standard therapy. Pediatric randomized
controlled trials on antibody B-cell lymphoma therapy have not
been published. The published clinical data consist of case reports,
case series, and phase I and II studies. Meinhardt et al. (2010)
report a response rate of 44% in a phase II window study of
Rituximab treatment of 87 children diagnosed with mature B-
NHL and Burkitt leukemia. Patients received the adult dose of
375 mg/m2 Rituximab during 5 days prior to starting chemother-
apy. Kumar et al. describe treatment results of six children with
follicular lymphoma treated with Rituximab (Goldman et al.,
2012) and multi-agent chemotherapy. Five of six treated patients
were in remission with a median follow-up of 31 months (Kumar
et al., 2011). Griffin et al. (2009) report combining Rituximab with
chemotherapy for six patients with diffuse large B-cell lymphoma
and 14 patients with Burkitt lymphoma and B-ALL. The over-
all response rate (complete and partial) was 60% with acceptable
toxicity. Finally, Goldman et al. (2012) recently reported treat-
ment results of 45 children and adolescents with stage III/IV B-cell
NHL treated with a combination FAB/LMB 96 chemotherapy and
Rituximab. The 3-year event-free and overall survival was 95%.
Currently, one phase 2/3, four phase 2, and one phase 1 study are
open for pediatric B-cell lymphoma patients (Table 1). Side effects
of Rituximab therapy in pediatric lymphoma patients are rarely
reported (Meinhardt et al., 2010; Goldman et al., 2012). It remains
to be determined if this is due to low incidence of side effects or
low patient numbers evaluated so far.
NEW CONCEPTS FOR B-CELL LYMPHOMA ANTIBODY
IMMUNOTHERAPY
While even the role of Rituximab in the treatment of pediatric
B-cell lymphomas still has to be evaluated, new concepts for anti-
body lymphoma immunotherapy are already evolving. The most
promising concepts focus on improving cytotoxicity of tumor-
specific antibodies, on targeting immune modulatory molecules
and the application of antibody combinations (Beck et al., 2010;
Weiner et al., 2010).
There are different ways to increase antibody cytotoxicity. One
of them is generation of bispecific antibodies. These antibodies
are directed against two target antigens, e.g., a tumor antigen,
such as CD19, and a molecule expressed on cytotoxic T-cells,
such as CD3. CD19/CD3-bispecific antibodies bring lymphoma
cells in close vicinity to cytotoxic T-cells thereby increasing killing
of lymphoma cells (Loffler et al., 2000). Blinatumomab, a bis-
pecific antibody targeting CD3 and CD19 has induced tumor
regression in adult B-cell NHL patients (Bargou et al., 2008).
Bispecific antibodies can also be directed against two antigens
both expressed by lymphoma cells. Recently, Gupta et al. (2012)
reported inducing lymphoma cell death with a bispecific anti-
body that crosslinks the B-cell antigens CD20 and CD74. Anti-
body glycoengineering is another important technique to increase
cytotoxicity via improved Fc-receptor binding. This technique
not only increases antibody-dependent cellular cytotoxicity, but
also Fc-receptor mediated phagocytosis and antigen presentation.
Obintuzumab (Braza et al., 2011), a glycoengineered anti-CD20
antibody has been tested in phase I studies in adult lymphoma
patients (Salles et al., 2012; Sehn et al., 2012). In both studies
heavily pretreated B-NHL patients received the antibody. Sehn
et al. report five patients (23%) with partial response and 12
(54%) with stable disease at the end of the induction period.
Salles et al. describe five complete and four partial responses (24
and 17%, respectively). A glycoengineered anti-CD19 antibody
(MEDI-551) has shown increased cellular cytotoxicity in vitro
and in murine animal models. The combination with Rituximab
resulted in prolonged suppression of lymphoma growth (Ward
et al., 2011).
Coupling of antibodies to cytotoxic agents (radionuclides,
immunotoxins) is a third way to increase clinical efficacy. Bren-
tuximab vedotin is a good example for this concept (Younes
et al., 2012b). The unconjugated antibody did not induce clinical
responses. Coupling of the same antibody to the cytotoxic agent
monomethyl auristatin E resulted in a therapeutic agent that has
received FDA approval for treatment of Hodgkin lymphoma in
2011.
Recently, antibodies targeting immune regulatory molecules
such as anti-CTLA-4 (Ipilimumab) (Ansell et al., 2009) and anti-
PD-1 (Norde et al., 2012; Pardoll, 2012; Topalian et al., 2012) have
shown clinical efficacy as anti-cancer treatment. In a phase I study
Ipilimumab induced a clinical response in 2 of 18 treated adult
B-NHL patients (one ongoing complete response >31 months
and a partial response lasting 19 months) (Ansell et al., 2009).
PD-1 ligand expression on primary Hodgkin/Reed-Sternberg cells
and PD-1 expression on HL-infiltrating T-cells has recently been
demonstrated. Blockade of PD-1 signaling restored IFNγ produc-
tion by lymphoma-infiltrating T-cells (Yamamoto et al., 2008).
Anti-PD-1 antibodies are currently evaluated as treatment for HL
and B-NHL in a phase I trial (NCT01592370).
Finally, combinational antibody therapy, e.g., combining anti-
bodies against two or more lymphoma antigens (Alinari et al.,
2011; Micallef et al., 2011; Ogura et al., 2012) or against a lym-
phoma antigen and an immune regulatory molecule, may further
improve therapeutic efficacy. Therapeutic antibodies are usu-
ally given in combination with chemotherapy. Optimizing this
chemoimmunotherapy to select the best antibody/chemotherapy
combinations may also increase therapeutic efficacy (Harrold
et al., 2012).
WAYS TO INCREASE PARTICIPATION OF CHILDREN IN NEW
DEVELOPMENTS OF ANTIBODY B-CELL LYMPHOMA
THERAPY
Experience with use of therapeutic antibodies in adult lym-
phoma patients is rapidly expanding. The successes of anti-
bodies such as Rituximab and Ipilimumab have sparked the
development of biosimilars (Carey, 2011), and of antibodies tar-
geting other lymphoma antigens or immune regulatory molecules.
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These developments increase therapeutic options for lymphoma
patients. Low patient numbers, however, make efficient clinical
testing of new antibody-based therapies for children in ran-
domized controlled trials in a timely fashion very difficult. This
excludes children from profiting from new therapeutic develop-
ments in an evidence-based manner. At the same time extrapola-
tion of adult data to pediatric patients is problematic, since tumor
and patient physiology differ significantly (Murphy, 1980; Deffen-
bacher et al., 2012). Especially for high risk or relapsed patients
this situation very much limits therapeutic options and may even
prevent any further therapy. However, children with rare, poten-
tially fatal diseases should be able to participate in new therapies
as fast as possible.
National and international registries of all pediatric B-cell
lymphoma patients receiving antibody-based therapies would
be a first step to increase available treatment data. In addi-
tion, antibody-therapy must be included and evaluated in future
national and international cooperative B-cell lymphoma therapy
trials. It is encouraging that currently at last six studies evaluating
Rituximab in pediatric B-cell lymphoma treatment are recruiting
patients (see Table 1 for an overview of clinical trials open for
children).
However, if clinical testing cannot be done in a timely fashion,
other options must be explored. In vitro screening of primary lym-
phoma cells for binding to therapeutic antibodies and subsequent
cytotoxicity can be a first step to choose therapeutic antibodies
for individual patients. Another way to assess antibody efficacy
may be in vivo testing in animal models, such as immunodefi-
cient mice harboring a human immune system (Traggiai et al.,
2004). Human B-cell lymphomas can be inoculated into these mice
containing an allogeneic, HLA-matched, or a syngenic human
immune system. Antibodies can then be administered to gener-
ate treatment efficiency data under conditions resembling patient
physiology as closely as possible. This experimental setup allows
preclinical testing of new antibodies, antibody combinations, or
chemoimmunotherapy. It may help to identify new targeted treat-
ment options for children with B-cell lymphoma to make more
evidence-based treatment choices for individual patients.
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